210 related articles for article (PubMed ID: 28177199)
1. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
[TBL] [Abstract][Full Text] [Related]
2. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
[TBL] [Abstract][Full Text] [Related]
3. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; McPhee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ
Hepatology; 2016 May; 63(5):1430-41. PubMed ID: 26822022
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Smirne C; D'Avolio A; Bellan M; Gualerzi A; Crobu MG; Pirisi M
Pharmacol Res Perspect; 2021 Aug; 9(4):e00811. PubMed ID: 34152088
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Poordad F; Shiffman ML; Ghesquiere W; Wong A; Huhn GD; Wong F; Ramji A; Shafran SD; McPhee F; Yang R; Noviello S; Linaberry M;
Antivir Ther; 2019; 24(1):35-44. PubMed ID: 30382942
[TBL] [Abstract][Full Text] [Related]
12. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Mangia A; Losappio R; Cenderello G; Potenza D; Mazzola M; De Stefano G; Terreni N; Copetti M; Minerva N; Piazzola V; Bacca D; Palmieri V; Sogari F; Santoro R
PLoS One; 2018; 13(7):e0200568. PubMed ID: 30063745
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
McCaughan GW; Thwaites PA; Roberts SK; Strasser SI; Mitchell J; Morales B; Mason S; Gow P; Wigg A; Tallis C; Jeffrey G; George J; Thompson AJ; Parker FC; Angus PW;
Aliment Pharmacol Ther; 2018 Feb; 47(3):401-411. PubMed ID: 29205432
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
16. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.
Lionetti R; Piccolo P; Lenci I; Siciliano M; Visco-Comandini U; De Santis A; Pompili M; Milana M; Taibi C; Dell'Isola S; Montalbano M; Mastroianni C; Begini P; Garbuglia AR; Angelico M; D'Offizi G
Ann Hepatol; 2019; 18(3):434-438. PubMed ID: 31023614
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Herzer K; Welzel TM; Spengler U; Hinrichsen H; Klinker H; Berg T; Ferenci P; Peck-Radosavljevic M; Inderson A; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Transpl Int; 2017 Mar; 30(3):243-255. PubMed ID: 28012215
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]